Hormone Replacement therapy advertising: Sense and nonsense on the web pages of the best-selling pharmaceuticals in spain

BMC Public Health

Volumn 10, Issue , 2010, Pages

  Chilet Rosell, Elisa ^a,b   Llaguno, Marta Martín ^a   Cantero, María Teresa Ruiz ^a,b   Alonso Coello, Pablo ^b,c  

^a UNIVERSITY OF ALICANTE   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; ARTICLE; COMMERCIAL PHENOMENA; DRUG INDUSTRY; HORMONE SUBSTITUTION; HUMAN; INTERNET; PHARMACY; SPAIN;

ADVERTISING AS TOPIC; COMMERCE; DRUG INDUSTRY; HORMONE REPLACEMENT THERAPY; HUMANS; INTERNET; PHARMACIES; SPAIN;

EID: 77950586594     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-134     Document Type: Article

References (23)

1. Hormone replacement therapy, cancer, controversies and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. N Krieger I Löwy R Aronowitz J Bigby, et al. J Epidemiol Community Health 2005 59 740 48 10.1136/jech.2005.033316 16100311
2. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Group for the Women's Health Initiative Investigators, JAMA 2002 288 321 333 10.1001/jama.288.3.321 12117397
3. Heart and Estrogen/Progestin Replacement Study (HERS): Design, methods and baseline characteristics. D Grady W Applegate TL Bush C Furberg B Riggs S Hulley, Control Clin Trials 1998 19 314 35 10.1016/S0197-2456(98)00010-5 9683309 (Pubitemid 28355757)
4. Exercise and Estrogen or Estrogen Alternatives (Phytoestrogens, Biphosphonates) for Prevention of Bone Mineral in Postmenopausal Women. PD Chilibeck, Canadian Journal of Applied Physiology 2004 29 59 75 15001805
5. Agency for Healthcare Research and Quality. Rockville MD: Hormone Replacement Therapy for the Prevention of Chronic Conditions in Postmenopausal Women. US Preventive Services Task Force, Topic Page 2005 http://ahrq.gov/ clinic/uspstf/uspspmho.htm
6. HRT in the early menopause: scientific evidence and common perceptions. Summary of the first IMS Global Summit on menopause-related issues. International Menopause Society, Climateric 2008 11 267 272
7. Restriction of the therapeutic indications of Hormone Replacement Therapy in Menopause. Spanish Agency of Medicines, General Subdepartment for Medicinal Products for Human Use 2004 http://www.aemps.es/actividad/alertas/usoHumano/ seguridad/THS-restriccion-enero04.htm Online document. Cited 15 April 2009
8. Hormone Therapy in Menopause. Updating of information. Spanish Agency of Medicines, General Subdepartment for Medicinal Products for Human Use 2008 http://www.aemps.es/actividad/alertas/usoHumano/seguridad/terapiaHormonal-oct08. htm Online document. Cited 15 April 2009
9. Promocián y publicidad farmacéutica: Quo Vadis? P Castillo Pérez, Med Clin (Barc) 1992 99 305 09 1453825
10. Internet, poblacián y medicamentos. Una relacián problemtica? Mesa Redonda: Difusián de informacián sobre salud en Internet. A Sanz Arrufat, http://www.prbb.org/quark/16/016091.htm Online document. Cited 15 April 2009
11. Communication from the Commission to the Council, the European Parliament, the Economic and Social Committee and the Committee of the Regions - eEurope 2002: Quality Criteria for Health related Websites. European Commission, /* COM/2002/0667 final */
12. European Federation of Pharmaceutical Industry Associations, Code on the Promotion of Prescription-Only Medicines to, and interactions with, healthcare professionals Brussels: EPFIA 1990
13. Code of good practices for the promotion of medicines, 2005. Farmaindustria, http://www.ifpma.org/fileadmin/templates/EthicalPromotion/pdfs/ ESP-en-Code2008.pdf Online document. Cited 15 April 2009
14. Jupiter media matrix search engine ratings, 2008. D Sullivan, http://searchenginewatch.com/2164801 Online document. Cited 15 April 2009
15. Information note for users of hormone replacement therapy with estrogen associated with progestin. Spanish Agency of Medicines, General Subdepartment of Medicinal Products for Human Use 2002 http://www.agemed.es/actividad/alertas/ docs/THS-usuarias.pdf Online document. Cited 15 April 2009
16. Tendencias en el uso de Internet como fuente de informacián sobre salud. Intervencián de salud en la red, 2007. J Jiménez Pernett JF García Gutiérrez JL Martín Jiménez C Bermdez-Tamayo, http://www.uoc.edu/uocpapers/4/dt/esp/jimenez.pdf Online document. Cited 15 April 2009
17. Informe anual sobre el desarrollo de la sociedad de la informacián en Espãa. Fundacián Orange Espãa, Fundacián Orange. Madrid, Gimeno M, 2007 http://www.fundacionorange.es/areas/25-publicaciones/ e2007.pdf Online document. Cited 15 April 2009
18. Casos Resueltos. Asociacián para la autorregulacián de la Comunicacián Comercial, Reclamaciones 2009 http://www.autocontrol.es/ Online document. Cited 15 April 2009
19. Disease Mongering in drug promotion: do governments have a regulatory role? B Mintzes, Plos Med 2006 3 4 461 5 10.1371/journal.pmed.0030198
20. Selling sickness: the pharmaceutical industry and disease mongering. R Moynihan I Heath D Henry, Br Med J 2002 324 886 91 10.1136/bmj.324.7342.886 (Pubitemid 34303943)
21. Drugs for pre-osteoporosis: prevention or disease mongering? P Alonso-Coello AL García-Franco G Guyatt R Moynihan, BMJ 2008 336 7636 126 9 10.1136/bmj.39435.656250.AD 18202066 (Pubitemid 351211963)
22. Search: visible and simple. Alertbox 2001. J Nielsen, http://www.useit.com/alertbox/20010513.html Accessed: 15 January 2009. [Online document. Cited 15 April 2009]
23. Canadian clinicians and patients need clean, clear knowledge. JA Muir Gray, CMAJ 2004 175 129